Ventajas de la medición de niveles plasmáticos de infliximab en pacientes con enfermedad inflamatoria intestinal

Autores/as

  • René Rojas B. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección de Gastroenterología
  • Natalia Covarrubias R. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección de Gastroenterología. Laboratorio de Gastroenterología
  • Julio Miranda B. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección de Gastroenterología. Laboratorio de Gastroenterología
  • Edith Pérez de Arce O. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección de Gastroenterología
  • Macarena Gompertz G. Hospital Clínico Universidad de Chile. Departamento de Medicina. Sección de Gastroenterología. Laboratorio de Gastroenterología

Resumen

Inflammatory bowel disease includes Crohn ́s disease, ulcerative colitis and unclassified colitis. Conventional therapies used for treating these diseases are often insufficient or contraindicated and biological agents have proved to be effective and safe in these cases. Infliximab is a quimeric IgG1 monoclonal anti-tumor necrosis factor antibody that is capable of inducing and mantaining clinical remission in patients with inflammatory bowel disease. Despite its proven efficacy a considerable group of patients lose response requiring changes in therapy. Serum Infliximab trough levels are correlated with clinical response, endoscopic remission and mucosal healing in patients with inflammatory bowel disease. Monitoring and adjusting therapy guided by drug serum levels have proved to be more cost-effective and safer than empiric adjustments. Current international guidelines recommend the measurement of Infliximab trough levels in the global evaluation and management of these patients to improve treatment, avoid adverse events and unnecessary costs.

Palabras clave:

Enfermedades Inflamatorias del Intestino, Infliximab